Vitamin D-binding protein: Difference between revisions

Jump to navigation Jump to search
m (Bot: HTTP→HTTPS (v470))
 
(Not a stub)
Line 10: Line 10:
It is able to bind the various forms of [[vitamin D]] including [[ergocalciferol]] (vitamin D<sub>2</sub>) and [[cholecalciferol]] (vitamin D<sub>3</sub>), the 25-hydroxylated forms ([[calcifediol]]), and the active hormonal product, 1,25-dihydroxyvitamin D ([[calcitriol]]).  The major proportion of vitamin D in blood is bound to this protein.  It transports vitamin D metabolites between skin, liver and kidney, and then on to the various target tissues.<ref name="entrez"/><ref name="Norman2008">{{cite journal | vauthors = Norman AW | title = From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health | journal = The American Journal of Clinical Nutrition | volume = 88 | issue = 2 | pages = 491S-499S | date = August 2008 | pmid = 18689389 }}</ref>
It is able to bind the various forms of [[vitamin D]] including [[ergocalciferol]] (vitamin D<sub>2</sub>) and [[cholecalciferol]] (vitamin D<sub>3</sub>), the 25-hydroxylated forms ([[calcifediol]]), and the active hormonal product, 1,25-dihydroxyvitamin D ([[calcitriol]]).  The major proportion of vitamin D in blood is bound to this protein.  It transports vitamin D metabolites between skin, liver and kidney, and then on to the various target tissues.<ref name="entrez"/><ref name="Norman2008">{{cite journal | vauthors = Norman AW | title = From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health | journal = The American Journal of Clinical Nutrition | volume = 88 | issue = 2 | pages = 491S-499S | date = August 2008 | pmid = 18689389 }}</ref>


As [[Gc-MAF|Gc protein-derived macrophage activating factor]] it is a [[Macrophage activating factor|Macrophage Activating Factor]] (MAF) that has been tested for use as a cancer treatment that would activate [[macrophage]]s against cancer cells.<ref>{{cite journal | vauthors = Yamamoto N, Suyama H, Yamamoto N | title = Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF | journal = Translational Oncology | volume = 1 | issue = 2 | pages = 65–72 | date = July 2008 | pmid = 18633461 | pmc = 2510818 | url = http://www.transonc.com/pdf/manuscript/v01i02/neo08106.pdf | format = [PDF] }}</ref>
As [[Gc-MAF|Gc protein-derived macrophage activating factor]] it is a [[Macrophage activating factor|Macrophage Activating Factor]] (MAF) that has been tested for use as a cancer treatment that would activate [[macrophage]]s against cancer cells.<ref>{{cite journal | vauthors = Yamamoto N, Suyama H, Yamamoto N | title = Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF | journal = Translational Oncology | volume = 1 | issue = 2 | pages = 65–72 | date = July 2008 | pmid = 18633461 | pmc = 2510818 | url = http://www.transonc.com/pdf/manuscript/v01i02/neo08106.pdf | format = [PDF] | doi=10.1593/tlo.08106}}</ref>


===Interactive pathway map===
===Interactive pathway map===
Line 19: Line 19:


== Genetic variation ==
== Genetic variation ==
Many genetic variants of the ''GC'' gene are known. They produce 6 main [[haplotype]]s and 3 main protein variants (Gc1S, Gc1F and Gc2).<ref name=Malik-2013/> The genetic variations are associated with differences in circulating 25-hydroxyvitamin D levels.<ref>{{cite journal | vauthors = McGrath JJ, Saha S, Burne TH, Eyles DW | title = A systematic review of the association between common single nucleotide polymorphisms and 25-hydroxyvitamin D concentrations | journal = The Journal of Steroid Biochemistry and Molecular Biology | volume = 121 | issue = 1-2 | pages = 471–7 | date = July 2010 | pmid = 20363324 | doi = 10.1016/j.jsbmb.2010.03.073 }}</ref> They have been proposed to account for some of the differences in vitamin D status in different ethnic groups,<ref>{{cite journal | vauthors = Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, Tamez H, Zhang D, Bhan I, Karumanchi SA, Powe NR, Thadhani R | title = Vitamin D-binding protein and vitamin D status of black Americans and white Americans | journal = The New England Journal of Medicine | volume = 369 | issue = 21 | pages = 1991–2000 | date = November 2013 | pmid = 24256378 | doi = 10.1056/NEJMoa1306357 }}</ref> and have been found to correlate with the response to vitamin D supplementation.<ref name=Malik-2013>{{cite journal | vauthors = Malik S, Fu L, Juras DJ, Karmali M, Wong BY, Gozdzik A, Cole DE | title = Common variants of the vitamin D binding protein gene and adverse health outcomes | journal = Critical Reviews in Clinical Laboratory Sciences | volume = 50 | issue = 1 | pages = 1–22 | date = January–February 2013 | pmid = 23427793 | pmc = 3613945 | doi = 10.3109/10408363.2012.750262 }}</ref>  
Many genetic variants of the ''GC'' gene are known. They produce 6 main [[haplotype]]s and 3 main protein variants (Gc1S, Gc1F and Gc2).<ref name=Malik-2013/> The genetic variations are associated with differences in circulating 25-hydroxyvitamin D levels.<ref>{{cite journal | vauthors = McGrath JJ, Saha S, Burne TH, Eyles DW | title = A systematic review of the association between common single nucleotide polymorphisms and 25-hydroxyvitamin D concentrations | journal = The Journal of Steroid Biochemistry and Molecular Biology | volume = 121 | issue = 1–2 | pages = 471–7 | date = July 2010 | pmid = 20363324 | doi = 10.1016/j.jsbmb.2010.03.073 }}</ref> They have been proposed to account for some of the differences in vitamin D status in different ethnic groups,<ref>{{cite journal | vauthors = Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, Tamez H, Zhang D, Bhan I, Karumanchi SA, Powe NR, Thadhani R | title = Vitamin D-binding protein and vitamin D status of black Americans and white Americans | journal = The New England Journal of Medicine | volume = 369 | issue = 21 | pages = 1991–2000 | date = November 2013 | pmid = 24256378 | doi = 10.1056/NEJMoa1306357 | pmc=4030388}}</ref> and have been found to correlate with the response to vitamin D supplementation.<ref name=Malik-2013>{{cite journal | vauthors = Malik S, Fu L, Juras DJ, Karmali M, Wong BY, Gozdzik A, Cole DE | title = Common variants of the vitamin D binding protein gene and adverse health outcomes | journal = Critical Reviews in Clinical Laboratory Sciences | volume = 50 | issue = 1 | pages = 1–22 | date = January–February 2013 | pmid = 23427793 | pmc = 3613945 | doi = 10.3109/10408363.2012.750262 }}</ref>  
{{-}}
{{-}}
== References ==
== References ==
Line 37: Line 37:
* {{cite journal | vauthors = Schoentgen F, Metz-Boutigue MH, Jollès J, Constans J, Jollès P | title = Complete amino acid sequence of human vitamin D-binding protein (group-specific component): evidence of a three-fold internal homology as in serum albumin and alpha-fetoprotein | journal = Biochimica et Biophysica Acta | volume = 871 | issue = 2 | pages = 189–98 | date = June 1986 | pmid = 2423133 | doi = 10.1016/0167-4838(86)90173-1 }}
* {{cite journal | vauthors = Schoentgen F, Metz-Boutigue MH, Jollès J, Constans J, Jollès P | title = Complete amino acid sequence of human vitamin D-binding protein (group-specific component): evidence of a three-fold internal homology as in serum albumin and alpha-fetoprotein | journal = Biochimica et Biophysica Acta | volume = 871 | issue = 2 | pages = 189–98 | date = June 1986 | pmid = 2423133 | doi = 10.1016/0167-4838(86)90173-1 }}
* {{cite journal | vauthors = McNearney TA, Odell C, Holers VM, Spear PG, Atkinson JP | title = Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity | journal = The Journal of Experimental Medicine | volume = 166 | issue = 5 | pages = 1525–35 | date = November 1987 | pmid = 2824652 | pmc = 2189652 | doi = 10.1084/jem.166.5.1525 }}
* {{cite journal | vauthors = McNearney TA, Odell C, Holers VM, Spear PG, Atkinson JP | title = Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity | journal = The Journal of Experimental Medicine | volume = 166 | issue = 5 | pages = 1525–35 | date = November 1987 | pmid = 2824652 | pmc = 2189652 | doi = 10.1084/jem.166.5.1525 }}
* {{cite journal | vauthors = Yang F, Naberhaus KH, Adrian GS, Gardella JM, Brissenden JE, Bowman BH | title = The vitamin D-binding protein gene contains conserved nucleotide sequences that respond to heavy metal, adipocyte and mitotic signals | journal = Gene | volume = 54 | issue = 2-3 | pages = 285–90 | year = 1987 | pmid = 2958390 | doi = 10.1016/0378-1119(87)90499-9 }}
* {{cite journal | vauthors = Yang F, Naberhaus KH, Adrian GS, Gardella JM, Brissenden JE, Bowman BH | title = The vitamin D-binding protein gene contains conserved nucleotide sequences that respond to heavy metal, adipocyte and mitotic signals | journal = Gene | volume = 54 | issue = 2–3 | pages = 285–90 | year = 1987 | pmid = 2958390 | doi = 10.1016/0378-1119(87)90499-9 }}
* {{cite journal | vauthors = Cooke NE, Willard HF, David EV, George DL | title = Direct regional assignment of the gene for vitamin D binding protein (Gc-globulin) to human chromosome 4q11-q13 and identification of an associated DNA polymorphism | journal = Human Genetics | volume = 73 | issue = 3 | pages = 225–9 | date = July 1986 | pmid = 3015768 | doi = 10.1007/BF00401232 }}
* {{cite journal | vauthors = Cooke NE, Willard HF, David EV, George DL | title = Direct regional assignment of the gene for vitamin D binding protein (Gc-globulin) to human chromosome 4q11-q13 and identification of an associated DNA polymorphism | journal = Human Genetics | volume = 73 | issue = 3 | pages = 225–9 | date = July 1986 | pmid = 3015768 | doi = 10.1007/BF00401232 }}
* {{cite journal | vauthors = Nestler JE, McLeod JF, Kowalski MA, Strauss JF, Haddad JG | title = Detection of vitamin D binding protein on the surface of cytotrophoblasts isolated from human placentae | journal = Endocrinology | volume = 120 | issue = 5 | pages = 1996–2002 | date = May 1987 | pmid = 3552627 | doi = 10.1210/endo-120-5-1996 }}
* {{cite journal | vauthors = Nestler JE, McLeod JF, Kowalski MA, Strauss JF, Haddad JG | title = Detection of vitamin D binding protein on the surface of cytotrophoblasts isolated from human placentae | journal = Endocrinology | volume = 120 | issue = 5 | pages = 1996–2002 | date = May 1987 | pmid = 3552627 | doi = 10.1210/endo-120-5-1996 }}
Line 50: Line 50:


[[Category:Vitamin D]]
[[Category:Vitamin D]]
{{gene-4-stub}}

Revision as of 21:49, 20 March 2018

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Vitamin D-binding protein (DBP), also/originally known as gc-globulin (group-specific component), is a protein that in humans is encoded by the GC gene.[1][2]

Structure

Human GC is a glycosylated alpha-globulin, ~58 kDa in size. Its 458 amino acids are coded for by 1690 nucleotides on chromosome 4 (4q11–q13). The primary structure contains 28 cysteine residues forming multiple disulfide bonds. GC contains 3 domains. Domain 1 is composed of 10 alpha helices, domain 2 of 9, and domain 3 of 4.[3]

Function

Vitamin D-binding protein belongs to the albumin gene family, together with human serum albumin and alpha-fetoprotein. It is a multifunctional protein found in plasma, ascitic fluid, cerebrospinal fluid and on the surface of many cell types.

It is able to bind the various forms of vitamin D including ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), the 25-hydroxylated forms (calcifediol), and the active hormonal product, 1,25-dihydroxyvitamin D (calcitriol). The major proportion of vitamin D in blood is bound to this protein. It transports vitamin D metabolites between skin, liver and kidney, and then on to the various target tissues.[2][4]

As Gc protein-derived macrophage activating factor it is a Macrophage Activating Factor (MAF) that has been tested for use as a cancer treatment that would activate macrophages against cancer cells.[5]

Interactive pathway map

Click on genes, proteins and metabolites below to link to respective articles. [§ 1]

[[File:
<imagemap> Image:VitaminDSynthesis WP1531.png
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
<imagemap> Image:VitaminDSynthesis WP1531.png
|{{{bSize}}}px|alt=Vitamin D Synthesis Pathway (view / edit)]]
Vitamin D Synthesis Pathway (view / edit)
  1. The interactive pathway map can be edited at WikiPathways: "VitaminDSynthesis_WP1531".

Production

It is synthesized by hepatic parenchymal cells and secreted into the [blood] circulation.[4]

Genetic variation

Many genetic variants of the GC gene are known. They produce 6 main haplotypes and 3 main protein variants (Gc1S, Gc1F and Gc2).[6] The genetic variations are associated with differences in circulating 25-hydroxyvitamin D levels.[7] They have been proposed to account for some of the differences in vitamin D status in different ethnic groups,[8] and have been found to correlate with the response to vitamin D supplementation.[6]

References

  1. Mikkelsen M, Jacobsen P, Henningsen K (Jul 1977). "Possible localization of Gc-System on chromosome 4. Loss of long arm 4 material associated with father-child incompatibility within the Gc-System". Human Heredity. 27 (2): 105–7. doi:10.1159/000152857. PMID 558959.
  2. 2.0 2.1 "Entrez Gene: GC group-specific component (vitamin D binding protein)".
  3. Verboven C, Rabijns A, De Maeyer M, Van Baelen H, Bouillon R, De Ranter C (February 2002). "A structural basis for the unique binding features of the human vitamin D-binding protein". Nature Structural Biology. 9 (2): 131–6. doi:10.1038/nsb754. PMID 11799400.
  4. 4.0 4.1 Norman AW (August 2008). "From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health". The American Journal of Clinical Nutrition. 88 (2): 491S–499S. PMID 18689389.
  5. Yamamoto N, Suyama H, Yamamoto N (July 2008). "Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF" ([PDF]). Translational Oncology. 1 (2): 65–72. doi:10.1593/tlo.08106. PMC 2510818. PMID 18633461.
  6. 6.0 6.1 Malik S, Fu L, Juras DJ, Karmali M, Wong BY, Gozdzik A, Cole DE (January–February 2013). "Common variants of the vitamin D binding protein gene and adverse health outcomes". Critical Reviews in Clinical Laboratory Sciences. 50 (1): 1–22. doi:10.3109/10408363.2012.750262. PMC 3613945. PMID 23427793.
  7. McGrath JJ, Saha S, Burne TH, Eyles DW (July 2010). "A systematic review of the association between common single nucleotide polymorphisms and 25-hydroxyvitamin D concentrations". The Journal of Steroid Biochemistry and Molecular Biology. 121 (1–2): 471–7. doi:10.1016/j.jsbmb.2010.03.073. PMID 20363324.
  8. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, Tamez H, Zhang D, Bhan I, Karumanchi SA, Powe NR, Thadhani R (November 2013). "Vitamin D-binding protein and vitamin D status of black Americans and white Americans". The New England Journal of Medicine. 369 (21): 1991–2000. doi:10.1056/NEJMoa1306357. PMC 4030388. PMID 24256378.

Further reading